Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599786 | 0.82 | CNR2 (0.35) | ALDH1A1CA14CTSSNFKB1NFKB2 | |
| SCHEMBL23227440 | 0.81 | CA14 (0.36) | ALDH1A1CA14ASGR1NFKB1NFKB2 | |
| SCHEMBL78691 | 0.80 | CA14 (0.41) | CA14CTSDCTSLCTSBCTSS | |
| SCHEMBL16318667 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CA14ASGR1CTSDCTSL | |
| SCHEMBL2810316 | 0.79 | CTSS (0.35) | CA14CTSS | |
| SCHEMBL21377451 | 0.79 | CA14 (0.33) | CA14ASGR1 | |
| SCHEMBL6680983 | 0.78 | CTSK (0.37) | CA14CTSSHDAC1HDAC6 | |
| SCHEMBL1022362 | 0.78 | ALDH1A1 (0.38) | ALDH1A1ASGR1CTSDCTSLCTSB | |
| SCHEMBL1022363 | 0.78 | ALDH1A1 (0.38) | ALDH1A1ASGR1CTSDCTSLCTSB | |
| SCHEMBL2579003 | 0.77 | CA14 (0.42) | CA14CTSDCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306285-A1 | Heat-Labile Prodrugs | ALEXZA PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008134668-A2 | HEAT-LABILE PRODRUGS | ALEXZA PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-0934065-B1 | NOVEL CRYPTOPHYCIN DERIVATIVES AS ANTI-NEOPLASTIC AGENTS | UNIV HAWAII (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6680311-B1 | ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | ELI LILLY AND COMPANY | 2004-01-20 | — | — | US | disclosed |
| EP-0934065-A4 | PHARMACEUTICAL COMPOUNDS | LILLY CO ELI (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-0934065-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998008505-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306285-A1 | Heat-Labile Prodrugs | HSP90AB1, HSP90AB2P, HSP90AA1 | ALDH1A1 74/4885CA14 2193/4885ASGR1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.